- Home
- SPNS vs IMCR Comparison
SPNS vs IMCR Comparison
Compare SPNS & IMCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPNS
- IMCR
- Stock Information
- Founded
- SPNS 1982
- IMCR 2008
- Country
- SPNS Israel
- IMCR United Kingdom
- Employees
- SPNS N/A
- IMCR N/A
- Industry
- SPNS Computer Software: Prepackaged Software
- IMCR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SPNS Technology
- IMCR Health Care
- Exchange
- SPNS Nasdaq
- IMCR Nasdaq
- Market Cap
- SPNS 1.6B
- IMCR 1.4B
- IPO Year
- SPNS 1992
- IMCR 2021
- Fundamental
- Price
- SPNS $27.35
- IMCR $29.20
- Analyst Decision
- SPNS Buy
- IMCR Buy
- Analyst Count
- SPNS 4
- IMCR 12
- Target Price
- SPNS $33.50
- IMCR $63.00
- AVG Volume (30 Days)
- SPNS 140.7K
- IMCR 372.8K
- Earning Date
- SPNS 05-07-2025
- IMCR 05-07-2025
- Dividend Yield
- SPNS 3.48%
- IMCR N/A
- EPS Growth
- SPNS 15.18
- IMCR N/A
- EPS
- SPNS 1.29
- IMCR N/A
- Revenue
- SPNS $542,379,000.00
- IMCR $310,202,000.00
- Revenue This Year
- SPNS $4.49
- IMCR $18.97
- Revenue Next Year
- SPNS $5.15
- IMCR $8.43
- P/E Ratio
- SPNS $21.14
- IMCR N/A
- Revenue Growth
- SPNS 5.40
- IMCR 24.36
- 52 Week Low
- SPNS $25.01
- IMCR $27.19
- 52 Week High
- SPNS $41.22
- IMCR $66.00
- Technical
- Relative Strength Index (RSI)
- SPNS 48.10
- IMCR 49.95
- Support Level
- SPNS $26.77
- IMCR $28.92
- Resistance Level
- SPNS $27.91
- IMCR $30.04
- Average True Range (ATR)
- SPNS 0.50
- IMCR 1.49
- MACD
- SPNS -0.03
- IMCR 0.10
- Stochastic Oscillator
- SPNS 37.04
- IMCR 53.71
About SPNS Sapiens International Corporation N.V. (Cayman Islands)
Sapiens International Corp NV is a provider of software solutions for the insurance industry, with an emerging focus on the financial services sector. The company offers software, solutions, and professional services for property & casualty (P&C); reinsurance; life, pension & annuity (L&A); workers' compensation (WC); medical professional liability (MPL); financial & compliance (F&C); and decision modeling for both insurance and financial markets. The group also provides services for project delivery and implementation services, for its Software Solutions portfolio. Geographically, it operates in the region of North America, Rest of the World, and Europe. It generates revenue from Europe.
About IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.